In severe cases it can be fatal because the condition reduces the motivation to breathe, his report adds. It's diagnosed using a combination of positron emission tomography and low scores on a motivation rating scale, previously validated in elite athletes. Drug therapy involves treatment by various drugs.
An Australian biotechnology company called Healthtec, advised by Argos, has had promising trial results of the new drug indolebant, and designed to help people with the condition, as Moynihan "One young man who could not leave his sofa is now working as an investment adviser in Sydney."
Professor David Henry of the University of Newcastle says, "While some extreme sufferers of MoDeD may benefit from indolebant, common laziness is not a disease. Some people might have a genuinely debilitating form of MoDeD but others are just plain lazy and have "an absolute right to just sit there."
Moynihan is critical of the role of Healthtec's promotion of MoDeD and what he calls the "corporate-sponsored creation of illness".
Moynihan says, "In almost any condition you take there are people at the severe end of the spectrum who benefit greatly from a medical label and from therapy including medication. I think that people who react negatively to this debate about disease mongering do a disservice to the genuinely ill."